🔗 Permalink

Inventor profile of:

Lyne Gagnon

City:

Laval

Country:

Canada

Published Applications:

Last publication date:

2023-11-02

Top Assignees for applications by Lyne Gagnon

The entities that hold a legal rights for patent applications filed by inventor Gagnon Lyne:

PROMETIC PHARMA SMT LIMITED 6 Cambridge, United Kingdom
PROMETIC BIOSCIENCES INC. 4 Laval, Quebec, Canada
Prometic Pharma SMT Limited 4 Comberton, Cambridge, United Kingdom
LIMINAL BIOSCIENCES LIMITED 3 Cambridge, United Kingdom
Prometic Biosciences Inc. 2 Mont-Royal, Canada
Prometic Biosciences Inc. 2 Quebec, Canada
LIMINAL BIOSCIENCES LIMITED 1 Comberton, United Kingdom
Prometic Biosciences Inc. 1 Laval, Canada
Prometic Biosciences, Inc. 1 Mont-Royal, Quebec, Canada
ProMetic BioSciences Inc. 1 Montreal, Quebec, Canada
PROMETIC BIOTHERAPEUTICS, INC. 1 Rockville, MD United States
Prometic Biosciences Inc. 1 Montreal, Canada

Recent patent applications by Gagnon Lyne

Lyne Gagnon from Laval, CA has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-11-02

US20230346893A1

Human necessities

Methods and Compositions for Preventing or Minimizing Epithelial-Mesenchymal Transition

#2 | 2023-04-06

US20230107538A1

Chemistry; metallurgy

CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF

#3 | 2021-10-28

US20210330761A1

Human necessities

Plasminogen treatment of conditions associated with PAI-1 overexpression

#4 | 2021-05-06

US20210128694A1

Human necessities

METHODS AND COMPOSITIONS FOR PREVENTING OR MINIMIZING EPITHELIAL-MESENCHYMAL TRANSITION

#5 | 2021-03-25

US20210085626A1

Human necessities

SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION

#6 | 2021-01-07

US20210002202A1

Chemistry; metallurgy

Substituted Aromatic Compounds and Pharmaceutical Uses Thereof

#7 | 2020-07-30

US20200237693A1

Human necessities

Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

#8 | 2020-06-04

US20200172462A1

Chemistry; metallurgy

Substituted aromatic compounds and related method for the treatment of fibrosis

#9 | 2020-03-12

US20200078324A1

Human necessities

Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration

#10 | 2020-01-16

US20200017432A1

Chemistry; metallurgy

Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

#11 | 2019-02-07

US20190038580A1

Human necessities

Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

#12 | 2018-08-23

US20180237374A1

Chemistry; metallurgy

Substituted aromatic compounds and related method for the treatment of fibrosis

#13 | 2018-08-16

US20180228750A1

Human necessities

SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS

#14 | 2018-06-14

US20180162799A1

Chemistry; metallurgy

Substituted aromatic compounds and pharmaceutical uses thereof

#15 | 2018-05-17

US20180134649A1

Chemistry; metallurgy

Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

#16 | 2017-11-02

US20170312237A1

Human necessities

Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration

#17 | 2017-07-27

US20170209399A1

Human necessities

Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

#18 | 2016-02-11

US20160039736A1

Chemistry; metallurgy

Substituted aromatic compounds and related method for the treatment of fibrosis

#19 | 2016-01-28

US20160023983A1

Chemistry; metallurgy

Substituted aromatic compounds for the treatment pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

#20 | 2015-11-05

US20150313856A1

Human necessities

Compounds and compositions for the treatment of cancer

#21 | 2015-04-02

US20150094372A1

Chemistry; metallurgy

Substituted aromatic compounds and pharmaceutical uses thereof

#22 | 2013-08-29

US20130225683A1

Human necessities

Compounds and Pharmaceutical Compositions for Uses in Diabetes

#23 | 2013-08-29

US20130225681A1

Chemistry; metallurgy

Phenylketone carboxylate compounds and pharmaceutical uses thereof

#24 | 2013-08-22

US20130217645A1

Human necessities

Compounds and compositions for the treatment of cancer

#25 | 2010-11-11

US20100286269A1

Human necessities

Medium-chain length fatty acids and glycerides as nephroprotection agents

#26 | 2010-10-28

US20100273731A1

Human necessities

Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

#27 | 2010-05-27

US20100129350A1

Chemistry; metallurgy

Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives

#28 | 2009-03-19

US20090075867A1

Human necessities

Triazine compounds and compositions thereof for the treatment of cancers

#29 | 2009-03-12

US20090068169A1

Chemistry; metallurgy

2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use

#30 | 2008-04-17

US20080090848A1

Human necessities

Substituted Purinyl Derivatives With Immunomodulator And Chemoprotective Activity And Use Alone Or With Medium-Chain Length Fatty Acids Or Glycerides

#31 | 2008-02-28

US20080051324A1

Human necessities

Medium-chain length fatty alcohols as stimulators of hematopoiesis

#32 | 2007-06-28

US20070149528A1

Chemistry; metallurgy

Triazine dimers for the treatment of autoimmune diseases

InventorID:

403236 ⎘